Genetic and Immunologic Interactions Driving STAT3 Signaling and Macrophage Polarization in Acute Myeloid Leukemia
7 affiliations
- 1Department of Biology, College of Education for Pure Science, Tikrit University, Tikrit 34001, Iraq
- 2Department of Medical Microbiology, College of Medicine, University of Kirkuk, Kirkuk 36001, Iraq
- 3Department of Medical Laboratory Technology, Erbil Health and Medical Technical College, Erbil Polytechnic University, Erbil 44001, Kurdistan Region, Iraq
- 4Department of Biology, College of Science, Al-Qalam University, Kirkuk 36001, Iraq
- 5College of Pharmacy, Cihan University-Erbil, Erbil 44001, Kurdistan Region, Iraq
- 6Department of Biology, College of Science, Salahaddin University-Erbil, Erbil 44001, Kurdistan Region, Iraq
- 7Department of Medical Science, Respiratory Medicine, and Allergology, Uppsala University and University Hospital, 75185 Uppsala, Sweden
Abstract
Acute myeloid leukemia (AML) is an increasingly recognized malignancy sustained by a dysregulated inflammatory niche, in which genetic alterations and microenvironmental signaling converge to drive pathogenesis. This review synthesizes emerging evidence linking genetic mutations and immune dysregulation in AML, proposing an integrated mutation-macrophage-signal transducer and activator of transcription 3 (STAT3) axis as a conceptual framework of disease progression. It proposes that mutations in CCAAT/enhancer-binding protein alpha (CEBPA) and Runt-related transcription factor 1 (RUNX1), despite conferring divergent genetic risk, converge on a common pathway of inflammatory cytokine overproduction, including interleukin-1 beta (IL-1β), tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), and interleukin-10 (IL-10), as well as C-C motif chemokine ligand 2 (CCL2)-mediated recruitment of tumor-associated macrophages. These educated macrophages are proposed to undergo M2-like polarization, releasing oncostatin M (OSM) and IL-6, which are positioned to activate the Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) survival pathway in leukemic blasts. Concurrently, IL-10 produced by regulatory T cells, stromal cells, and M2-like polarized macrophages within the leukemic niche signals through its cognate receptor to potently activate STAT3, suppressing antigen-presenting cell function, downregulating major histocompatibility complex class II (MHC class II) expression, and impairing effective anti-tumor T-cell immunity, thereby potentially reinforcing the immunosuppressive architecture that shields leukemic blasts from immune surveillance. This proposed feed-forward loop is associated with transcriptional upregulation of the anti-apoptotic factor BCL2-like 1 (BCL2L1) and the negative-feedback regulator suppressor of cytokine signaling 3 (SOCS3), a pattern consistent with chemoresistance and impaired negative-feedback control of STAT3 signaling. Translational biomarkers, including OSM, IL-6, IL-10, and SOCS3/BCL2L1 transcripts, may quantify this axis, offering a dynamic, functional complement to static genetic risk stratification. Ultimately, this proposed triad suggests that aberrant inflammation may represent a shared therapeutic vulnerability; targeting the IL-6/oncostatin M receptor (OSMR)/STAT3 signaling nodes or reprogramming macrophage polarization could, if validated, disrupt this circuit in selected mutational subtypes.
Related
- Tangeretin ameliorates osteoarthritis and suppresses synovial macrophage M1 polarization in association with suppression of NF-κB signaling
- 697 Sex-biased macrophage polarization and CD8+ T cell suppression downstream of Yap1-CD276 signaling in medulloblastoma
- High-Calorie Diet Aggravates Lipopolysaccharide-Induced Pulmonary Inflammation in Juvenile Mice: Association of Acetate-Mediated Macrophage Polarization with AMPK/YAP Signaling
- Sprayable phage-cocktail hydrogel promotes diabetic wound healing through macrophage M2 polarization and restoring SP and CGRP signaling axis
- Magnesium cantharidate suppresses hepatocellular carcinoma progression and modulates tumor-associated macrophage polarization: potential involvement of ERK1/2 signaling and de novo serine synthesis
BibTeX
@article{ahmed2026genetic,
title = {{Genetic and Immunologic Interactions Driving STAT3 Signaling and Macrophage Polarization in Acute Myeloid Leukemia}},
author = {Kvan Omar Ahmed and Measer Abdullah Ahmed and Goran Othman and Shukur Wasman Smail},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27208957},
url = {https://www.mdpi.com/1422-0067/27/20/8957},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Genetic and Immunologic Interactions Driving STAT3 Signaling and Macrophage Polarization in Acute Myeloid Leukemia
AU - Kvan Omar Ahmed
AU - Measer Abdullah Ahmed
AU - Goran Othman
AU - Shukur Wasman Smail
PY - 2026
DA - 2026/10/01
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27208957
UR - https://www.mdpi.com/1422-0067/27/20/8957
AB - Acute myeloid leukemia (AML) is an increasingly recognized malignancy sustained by a dysregulated inflammatory niche, in which genetic alterations and microenvironmental signaling converge to drive pathogenesis. This review synthesizes emerging evidence linking genetic mutations and immune dysregulation in AML, proposing an integrated mutation-macrophage-signal transducer and activator of transcription 3 (STAT3) axis as a conceptual framework of disease progression. It proposes that mutations in CCAAT/enhancer-binding protein alpha (CEBPA) and Runt-related transcription factor 1 (RUNX1), despite conferring divergent genetic risk, converge on a common pathway of inflammatory cytokine overproduction, including interleukin-1 beta (IL-1β), tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), and interleukin-10 (IL-10), as well as C-C motif chemokine ligand 2 (CCL2)-mediated recruitment of tumor-associated macrophages. These educated macrophages are proposed to undergo M2-like polarization, releasing oncostatin M (OSM) and IL-6, which are positioned to activate the Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) survival pathway in leukemic blasts. Concurrently, IL-10 produced by regulatory T cells, stromal cells, and M2-like polarized macrophages within the leukemic niche signals through its cognate receptor to potently activate STAT3, suppressing antigen-presenting cell function, downregulating major histocompatibility complex class II (MHC class II) expression, and impairing effective anti-tumor T-cell immunity, thereby potentially reinforcing the immunosuppressive architecture that shields leukemic blasts from immune surveillance. This proposed feed-forward loop is associated with transcriptional upregulation of the anti-apoptotic factor BCL2-like 1 (BCL2L1) and the negative-feedback regulator suppressor of cytokine signaling 3 (SOCS3), a pattern consistent with chemoresistance and impaired negative-feedback control of STAT3 signaling. Translational biomarkers, including OSM, IL-6, IL-10, and SOCS3/BCL2L1 transcripts, may quantify this axis, offering a dynamic, functional complement to static genetic risk stratification. Ultimately, this proposed triad suggests that aberrant inflammation may represent a shared therapeutic vulnerability; targeting the IL-6/oncostatin M receptor (OSMR)/STAT3 signaling nodes or reprogramming macrophage polarization could, if validated, disrupt this circuit in selected mutational subtypes.
SN - 1422-0067
ER -